Salarius pharmaceuticals, inc. (FLKS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14
Grant revenue

1,132

1,769

874

164

655

163

469

245

178

282

413

335

242

-

-

-

-

-

-

-

-

-

-

-

Net product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

291

586

112

0

-

0

0

-

-

-

-

Other revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

7

12

0

0

-

0

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

298

599

112

0

-

0

-

-

-

-

-

Operating expenses:
Cost of product revenue

-

-

-

36

-

74

-

179

83

133

148

145

79

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

133

221

110

197

0

0

0

0

-

-

-

Research and development

1,643

2,148

1,140

29

699

187

353

6,174

4,680

4,259

4,739

4,076

3,914

4,230

5,665

6,094

4,387

3,309

3,445

3,190

2,804

1,965

909

1,099

General and administrative

1,859

1,231

3,494

1,497

1,488

1,921

428

2,994

3,697

3,983

4,934

4,990

4,594

3,918

5,447

5,377

5,111

4,621

4,722

3,904

3,216

1,786

1,084

1,092

Total operating expenses

3,502

3,343

4,635

1,562

2,188

2,184

782

9,349

8,461

8,375

9,823

9,212

8,588

8,283

11,334

11,583

9,695

7,930

8,167

7,094

6,021

3,751

1,993

2,192

Loss before other income (expense)

-2,369

-1,573

-3,760

-1,398

-1,532

-2,021

-313

-9,103

-8,282

-8,092

-9,409

-8,876

-8,346

-7,984

-10,735

-11,470

-9,695

-

-8,167

-

-

-

-

-

Change in fair value of warrant liability

-283

-

-1,130

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income net

2

-

-0

-

10

-

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-2,630

-

-

-

-307

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income from discontinued operations

-

-

2

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,930

-

-7,094

-6,021

-3,751

-1,993

-2,192

Interest income, net

-

-

-

13

-

12

-

51

59

64

77

72

77

84

97

107

103

37

14

16

3

9

6

2

Net loss

-2,083

-1,401

-2,627

-1,384

-1,522

-2,008

-307

-9,051

-8,223

-8,028

-9,332

-8,804

-8,268

-7,900

-10,637

-11,363

-9,592

-7,892

-8,152

-7,078

-6,017

-3,742

-1,986

-2,189

Preferred dividends

-

-

0

-

-

-

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations attributable to common stockholders

-

-

-2,630

-

-

-

-332

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share — basic and diluted
Continuing operations (usd per share)

-

-

-0.73

-

-

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (usd per share)

-

-

0.00

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-1,384

-

-

-

-9,051

-8,223

-

-

-

-

-

-

-

-

-7,892

-8,152

-7,078

-6,017

-

-

-

Net loss per share (usd per share)

-0.22

-0.67

-0.73

-0.08

-0.64

-0.11

-0.20

-0.50

-0.46

-0.46

-0.54

-0.51

-0.49

-0.48

-0.65

-0.71

-0.61

-0.51

-0.53

-0.47

-0.59

-1.82

-1.11

-1.42

Weighted-average number of common shares outstanding — basic and diluted

9,534

-10,972

3,605

18,068

2,372

18,067

1,653

18,037

17,893

17,642

17,386

17,130

16,873

16,619

16,361

16,105

15,843

15,551

15,290

15,034

10,179

2,061

1,797

1,539

Net product revenue
Total revenue

-

-

-

163

-

161

-

241

176

282

407

330

240

-

-

-

-

-

-

-

-

-

-

-

Other revenue
Total revenue

-

-

-

1

-

1

-

4

2

0

6

4

2

-

-

-

-

-

-

-

-

-

-

-